Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRAJ7 (T cell receptor alpha joining 7) is a gene segment within the T cell receptor alpha locus, encoding one of many possible joining regions recombined during T cell development. VJ recombination in the alpha locus uses TRAJ segments like TRAJ7 to generate the antigen-binding diversity found in T cell receptors. TRAJ7 does not encode a protein by itself; instead, it contributes as a module to the assembled variable region of the receptor as part of somatic DNA rearrangement[1][3][4]. TRAJ7 is not a pharmacological target, but it is essential for immune diversity and function as part of the broader TCR complex[2][5]. If you require information on the complete *T cell receptor alpha chain* or the *T cell receptor complex*—which are canonical therapeutic targets—please clarify, as TRAJ7 alone is a joining segment and not a conventional drug target[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 7 (TRAJ7).